Core Viewpoint - Addex Therapeutics announced that its spin-out company, Neurosterix, has initiated a Phase 1 clinical study of NTX-253, a positive allosteric modulator for the treatment of schizophrenia, marking a significant milestone for both companies [1][2] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4] - The company retains a 20% equity interest in Neurosterix, which was spun out in April 2024 and raised $65 million in Series A financing [2][4] Product Development - NTX-253 is a selective, orally available positive allosteric modulator of the muscarinic M4 receptor, designed to treat schizophrenia by potentially reducing psychosis symptoms without the side effects associated with traditional dopamine antagonists [1][3] - Preclinical studies have shown that NTX-253 has robust antipsychotic-like activity and a favorable safety profile, supporting its advancement into first-in-human clinical studies [3] Market Position - The M4 muscarinic receptor is a validated target for treating schizophrenia, offering a novel therapeutic approach compared to traditional antipsychotics that primarily target dopamine receptors [3] - Current antipsychotics can induce metabolic, cognitive, and motor side effects, which M4 PAMs aim to avoid while still providing therapeutic benefits [3]

Core Viewpoint - Addex Therapeutics announced that its spin-out company, Neurosterix, has initiated a Phase 1 clinical study of NTX-253, a positive allosteric modulator for the treatment of schizophrenia, marking a significant milestone for both companies [1][2]. Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4]. - The company retains a 20% equity interest in Neurosterix, which was spun out in April 2024 and raised $65 million in Series A financing [2][4]. Product Development - NTX-253 is a selective, orally available positive allosteric modulator of the muscarinic M4 receptor, designed to treat schizophrenia by potentially reducing psychosis symptoms without the side effects associated with traditional dopamine antagonists [1][3]. - Preclinical studies have shown that NTX-253 has robust antipsychotic-like activity and a favorable safety profile, supporting its advancement into first-in-human clinical studies [3]. Market Position - The M4 muscarinic receptor is recognized as a validated target for treating schizophrenia, offering a novel therapeutic approach compared to existing dopamine receptor antagonists [3]. - Current antipsychotics primarily target dopamine receptors, which can lead to metabolic, cognitive, and motor side effects, highlighting the potential advantages of M4 PAMs like NTX-253 [3].

Core Viewpoint - Addex Therapeutics has amended its At The Market Offering Agreement with H.C. Wainwright & Co. to allow for the sale of American Depositary Shares (ADSs) with an aggregate offering price of up to $3.3 million [1] Group 1: Offering Details - The amended ATM Agreement enables Addex to sell ADSs at its discretion through H.C. Wainwright & Co. [1] - H.C. Wainwright & Co. will sell the ADSs using methods permitted by law, including sales on The Nasdaq Capital Market [2] - The sales commission for H.C. Wainwright & Co. is set at three percent (3.0%) of the gross sales proceeds from any ADSs sold [2] Group 2: Company Background - Addex Therapeutics is focused on developing novel small molecule allosteric modulators for neurological disorders [5] - The lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [5] - Addex has partnerships for developing GABAB PAM drug candidates for substance use disorders and is advancing an independent GABAB PAM program for chronic cough [5] Group 3: Corporate Structure - Addex holds a 20% equity interest in Neurosterix US Holdings LLC, which is advancing allosteric modulator programs for various mental health disorders [5] - The company has also invested in Stalicla, a private Swiss company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders [5] Group 4: Stock Information - Addex shares are listed on the SIX Swiss Exchange and NASDAQ Capital Market under the ticker symbol "ADXN" [6]

Core Insights - Addex Therapeutics reported its financial results for Q3 and YTD 2025, highlighting a focus on developing novel small molecule allosteric modulators for neurological disorders [1][4] Financial Performance - Income for Q3 2025 was CHF 50,000, a decrease of CHF 8,000 from Q3 2024, and year-to-date income was CHF 157,000, down CHF 251,000 compared to the same period in 2024 [3] - R&D expenses increased to CHF 228,000 in Q3 2025 from CHF 204,000 in Q3 2024, while year-to-date R&D expenses decreased to CHF 619,000 from CHF 789,000 [3][5] - G&A expenses for Q3 2025 were CHF 518,000, up from CHF 476,000 in Q3 2024, with year-to-date G&A expenses decreasing to CHF 1,573,000 from CHF 1,929,000 [3][6] - The total operating loss for Q3 2025 was CHF 696,000, compared to CHF 622,000 in Q3 2024, with a year-to-date total operating loss of CHF 2,035,000, an improvement from CHF 2,310,000 [3] - Net loss from continuing operations for Q3 2025 was CHF 1,577,000, slightly higher than CHF 1,528,000 in Q3 2024, while year-to-date net loss increased to CHF 5,009,000 from CHF 3,720,000 [3][8] - Basic and diluted net loss per share for the nine-month period was CHF 0.05, compared to a profit of CHF 0.08 in the same period of 2024 [9] Cash Position - Cash and cash equivalents decreased to CHF 2.2 million as of September 30, 2025, from CHF 3.3 million a year earlier, primarily due to operating activities [10] Corporate Developments - The company is advancing its GABAB positive allosteric modulator candidate for chronic cough and dipraglurant for post-stroke recovery [2][14] - Addex holds a 20% equity interest in Neurosterix US Holdings LLC, which is developing a portfolio of allosteric modulator programs [14]

Core Viewpoint - Addex Therapeutics will report its Q3 2025 financial results on December 4, 2025, and provide a business update along with a review of its product pipeline during a teleconference and webcast [1] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [3] - The lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [3] - Addex's partner, Indivior, is developing a GABAB PAM drug candidate for substance use disorders, having completed IND enabling studies [3] - The company is also advancing an independent GABAB PAM program for chronic cough [3] - Addex holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for schizophrenia, psychosis, mood-related disorders, and mood disorders [3] - Additionally, Addex has invested in Stalicla, a private Swiss company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders [3] Financial Information - Addex shares are listed on the SIX Swiss Exchange and NASDAQ Capital Market under the ticker symbol "ADXN" [4]

Core Points - Addex Therapeutics has issued 34,300,000 new registered shares at a nominal value of CHF 0.01, fully subscribed by its wholly-owned subsidiary, Addex Pharma S.A, to enhance future financing flexibility [1] - The total issued share capital has increased to CHF 2,186,544.96, with a total of 218,654,496 shares issued, while the number of outstanding shares remains unchanged [1] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [2] - The lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [2] - Addex has partnered with Indivior for a GABAB PAM drug candidate aimed at substance use disorders, which has completed IND enabling studies [2] - The company is also advancing an independent GABAB PAM program for chronic cough and holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for various neurological conditions [2] - Additionally, Addex has invested in Stalicla, a private Swiss company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders [2] Stock Information - Addex shares are listed on the SIX Swiss Exchange and NASDAQ under the ticker symbol "ADXN" [3]

Core Viewpoint - Addex Therapeutics reported significant progress in drug development and business milestones during the first half of 2025, particularly with its GABAB PAM drug candidate for chronic cough and the mGlu2 PAM asset ADX71149 [2][5][16] Financial Performance - Income for H1 2025 decreased to CHF 107,000 from CHF 350,000 in H1 2024, a decline of CHF 243,000 [4] - R&D expenses reduced to CHF 391,000 in H1 2025 from CHF 584,000 in H1 2024, reflecting a decrease of CHF 193,000 [4][8] - G&A expenses decreased to CHF 1,056,000 in H1 2025 from CHF 1,453,000 in H1 2024, a reduction of CHF 397,000 [4][9] - Total operating loss improved to CHF 1,340,000 in H1 2025 from CHF 1,687,000 in H1 2024, an improvement of CHF 347,000 [4] - Net loss from continuing operations increased to CHF 3,432,000 in H1 2025 from CHF 2,192,000 in H1 2024, an increase of CHF 1,240,000 [4][10] - Basic and diluted loss per share was CHF 0.03 for H1 2025 compared to a profit of CHF 0.10 for H1 2024 [11] Cash Position - Cash and cash equivalents decreased to CHF 2.3 million as of June 30, 2025, down from CHF 3.8 million as of June 30, 2024, a decrease of CHF 1.5 million [7][11] Corporate Developments - The GABAB PAM chronic cough candidate showed robust anti-tussive activity in multiple disease models [5][6] - The company regained rights to the Phase 2 mGlu2 PAM asset, ADX71149, and is evaluating next steps internally [2][5] - An option agreement was entered with Sinntaxis for exclusive licensing of intellectual property related to mGlu5 NAM in brain injury recovery [2][5] - Indivior successfully advanced its GABAB PAM program for substance use disorders through IND enabling studies [5][6] - The company invested in Stalicla, reinforcing its commitment to innovative treatments for CNS disorders [2][5][16]

Core Viewpoint - Addex Therapeutics reported significant progress in drug development and business milestones during the first half of 2025, particularly with its GABAB PAM drug candidate for chronic cough and the mGlu2 PAM asset ADX71149 [2][5][16] Financial Performance - Income for H1 2025 decreased to CHF 107,000 from CHF 350,000 in H1 2024, a decline of CHF 243,000 [4] - R&D expenses reduced to CHF 391,000 in H1 2025 from CHF 584,000 in H1 2024, an improvement of CHF 193,000 [4][8] - G&A expenses decreased to CHF 1,056,000 in H1 2025 from CHF 1,453,000 in H1 2024, a reduction of CHF 397,000 [4][9] - Total operating loss improved to CHF 1,340,000 in H1 2025 from CHF 1,687,000 in H1 2024, a decrease of CHF 347,000 [4] - Net loss from continuing operations increased to CHF 3,432,000 in H1 2025 from CHF 2,192,000 in H1 2024, an increase of CHF 1,240,000 [4][10] - Basic and diluted loss per share was CHF 0.03 for H1 2025 compared to a profit of CHF 0.10 for H1 2024 [7][11] - Cash position decreased to CHF 2.3 million at the end of H1 2025 from CHF 3.8 million at the end of H1 2024 [5][11] Operational Highlights - The GABAB PAM chronic cough candidate showed robust anti-tussive activity in multiple disease models [5][6] - Rights to the Phase 2 mGlu2 PAM asset, ADX71149, were regained, with internal evaluations for next steps ongoing [2][5] - Indivior successfully advanced its GABAB PAM program for substance use disorders through IND enabling studies [5][6] - An option agreement was entered with Sinntaxis for exclusive licensing of intellectual property related to mGlu5 NAM in brain injury recovery [5][6] - Investment in Stalicla SA was made, reinforcing the commitment to innovative treatments for CNS disorders [5][6][16]

Core Viewpoint - Addex Therapeutics is set to report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025, followed by a conference call on October 1, 2025, to discuss the results and provide a business update [1][2]. Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [3]. - The lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [3]. - Addex has a partnership with Indivior for a GABAB PAM drug candidate aimed at substance use disorders, which has completed IND enabling studies [3]. - The company is also advancing an independent GABAB PAM program for chronic cough and holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for various neurological conditions [3]. Upcoming Events - The conference call to discuss the financial results will take place on October 1, 2025, at 16:00 CEST, with participation from CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev [1][2].

Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [3] - The lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [3] - Addex has a partnership with Indivior for a GABAB PAM drug candidate aimed at substance use disorders, which has completed IND enabling studies [3] - The company is also advancing an independent GABAB PAM program for chronic cough and holds a 20% equity interest in Neurosterix LLC, which is developing allosteric modulator programs for various neurological conditions [3] Recent Developments - Addex Therapeutics announced the appointment of the Bank of New-York Mellon (BNY) as its new ADS depositary agent, effective October 6, 2025 [1] - The appointment of BNY will not impact the fees paid by ADS holders, and no action is required from them at the effective date [2] Stock Information - Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares are listed on the NASDAQ Capital Market under the ticker symbol "ADXN" [3]